Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes

Peter Jentsch, Madhur Anand, Chris T. Bauch
doi: https://doi.org/10.1101/2020.09.25.20201889
Peter Jentsch
1Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada
2School of Environmental Sciences, University of Guelph, Guelph, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhur Anand
1Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris T. Bauch
2School of Environmental Sciences, University of Guelph, Guelph, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cbauch@uwaterloo.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

During the COVID-19 pandemic, authorities must decide which groups to prioritise for vaccination. These decision will occur in a constantly shifting social-epidemiological landscape where the success of large-scale non-pharmaceutical interventions (NPIs) like physical distancing requires broad population acceptance. We developed a coupled social-epidemiological model of SARS-CoV-2 transmission. Schools and workplaces are closed and re-opened based on reported cases. We used evolutionary game theory and mobility data to model individual adherence to NPIs. We explored the impact of vaccinating 60+ year-olds first; <20 year-olds first; uniformly by age; and a novel contact-based strategy. The last three strategies interrupt transmission while the first targets a vulnerable group. Vaccination rates ranged from 0.5% to 4.5% of the population per week, beginning in January or July 2021. Case notifications, NPI adherence, and lockdown periods undergo successive waves during the simulated pandemic. Vaccination reduces median deaths by 32% − 77% (22% − 63%) for January (July) availability, depending on the scenario. Vaccinating 60+ year-olds first prevents more deaths (up to 8% more) than transmission-interrupting strategies for January vaccine availability across most parameter regimes. In contrast, transmission-interrupting strategies prevent up to 33% more deaths than vaccinating 60+ year-olds first for July availability, due to higher levels of natural immunity by that time. Sensitivity analysis supports the findings. Further research is urgently needed to determine which populations can benefit from using SARS-CoV-2 vaccines to interrupt transmission.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded by the Ontario Ministry of Colleges and Universities and the Natural Sciences and Engineering Research Council of Canada. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Removed journal-specific formatting requirements.

Data Availability

All data used in the manuscript are publicly available. Model code is available upon request from the co-authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 27, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes
Peter Jentsch, Madhur Anand, Chris T. Bauch
medRxiv 2020.09.25.20201889; doi: https://doi.org/10.1101/2020.09.25.20201889
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes
Peter Jentsch, Madhur Anand, Chris T. Bauch
medRxiv 2020.09.25.20201889; doi: https://doi.org/10.1101/2020.09.25.20201889

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (527)
  • Epidemiology (9993)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2440)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1634)
  • Health Policy (750)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (529)
  • Infectious Diseases (except HIV/AIDS) (11849)
  • Intensive Care and Critical Care Medicine (624)
  • Medical Education (251)
  • Medical Ethics (73)
  • Nephrology (267)
  • Neurology (2271)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1242)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (727)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (280)
  • Psychiatry and Clinical Psychology (2277)
  • Public and Global Health (4820)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (487)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (123)
  • Urology (99)